je.st
news
Home
› Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Inc. Focused On GPCR Targets Across Multiple Therapeutic Areas
Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Inc. Focused On GPCR Targets Across Multiple Therapeutic Areas
2015-12-02 01:37:23| drugdiscoveryonline Home Page
Sosei Group Corporation (“Sosei”) recently announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas
Tags: areas
multiple
drug
focused
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||